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FORECASTING BRANDED AND GENERIC 
PHARMACEUTICAL LIFE CYCLES
1
Presentation Structure
 Previous Research – Product Lifecycle
 Pharmaceutical Market
 Research Project – Aims
 Research Project - The Data
 Preliminary Results
 Graph Categories
 Next Steps 
2
Previous Research – Product Life Cycle
3
Pharmaceutical Market
 Moss (2008) states that research has focused on consumer 
products and brands disregarding other products and brands such 
as pharmaceuticals. 
 Highly competitive non assembled global industry
 In 2007 the top 10 pharmaceutical companies had a combined 
sales of just under £150 billion and commanded 45% market share
 2 of these were UK companies – AstraZeneca and 
GlaxoSmithKline
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Pharmaceutical Market continued
 In 2008 £4 billion was spent on R&D however this was expected to 
decrease due to the financial climate
 Patent Expiration – Major Problem
 UK patents last for 20 years from application
 5 year extension can be applied for
 Generics enter the market
 NHS and other health/government organisations always looking at ways 
to curb the rising cost of healthcare
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Pharmaceutical Market continued
 A branded drug is one made by a specific pharmaceutical 
company and is therefore given a name. The generic is the 
key compound that makes up the drug. In some cases the 
company can market both the branded and generic to appeal 
to a wider audience. An example is Sertraline.
 Brand name – Lustral by Pfizer
 Generic name – Sertraline.
6
Research project - aims
 Aims
1. To classify the patterns that are exhibited during the product 
lifecycle of pharmaceutical drugs
2. Model these patterns 
3. Forecast the patterns over time
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Research Project – The Data
 JIGSAW database
 Established in 1985 by ISIS research for the purposes of academic 
research
 Data from 1987 -2008
 2.57 million script records
 Self Report Questionnaires from GP’s
 Data is specifically relating to what drugs are prescribed
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Pharmaceutical Life Cycle types
 Based on the current research there are three types of 
pharmaceutical life cycle including both a branded and a 
generic strand.
 Branded then Generic
 High Branded Low Generic
 High Generic Low Branded
 The major group that this paper focuses on is the Branded 
then Generic category
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Branded Then Generic
10
Branded then Generic
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Models used in the current research
 Initial research focused on using the following models:
 Naïve Model
 Moving Average Model
 Single Exponential Smoothing (SES)
 Repeat Purchase Diffusion Model (RPDM)
 Bass Diffusion Model
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Results – Branded then Generic
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Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Branded Drugs
Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Generic Drugs
Naïve Methods
Exponential 
Smoothing Diffusion Models
Naive
Moving 
Average SES Bass RPDM
ME -90.13 -178.84 -127.7 -530.24 -440.69
RAE 1 1.84 1.44 5.07 4.92
MSE 188674.9 386082.2 274580.69 1192661 1105040
Naïve Methods Exponential Smoothing Diffusion Models
Naive Moving Average SES Bass RPDM
ME -178.32 -281.39 -261.07 -702.8 -659.96
RAE 1 1.93 1.26 3.56 3.61
MSE 97114.84 382981.9 223314.99 942576.8 928290.7
Results – Branded then Generic
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Naïve + Drift Errors of Branded Drugs for the BTG Category
Naïve + Drift Errors of Generic Drugs for the BTG Category
Level of Drift Compared with RAE for Branded and 
Generic Pharmaceutical Life Cycles
Extra Models
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 A number of other models were then applied 
 Holt Winters Exponential Smoothing
 ARIMA
 Robust Regression
 Regression over t-1
Results – Branded then Generic
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Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Branded Drugs
Forecasting Bias, Accuracy and Variance (ME, RAE, MSE) of Generic Drugs
Naïve Methods
Exponential 
Smoothing ARIMA
Naive
Naïve + 
20% Drift HOLT ARIMA
Regression 
over t
Regression 
over t-1
Robust 
Regression
ME -90.13 -72.73 -65.71 -35.44 42.81 15.56 -32.38
RAE 1 0.98 1.41 0.97 2.53 2.51 1.01
MSE 188674.9 179087.2 205963.3 54479.69 418275.29 399378.49 60658.01
Regression Models
Exponential 
Smoothing ARIMA
Naive
Naïve + 
70% Drift HOLT ARIMA
Regression 
over t
Regression 
over t-1
Robust 
Regression
ME -178.32 -73.39 -76.72 -199.5 -132.49 -144.87 -183.03
RAE 1 0.67 0.81 1.58 1.91 1.87 1.49
MSE 97114.84 63699,45 70617.16 202183.5 252106.86 240559.86 178817.42
Regression ModelsNaïve Methods
Conclusions
 GP’s within the UK have a tendency to prescribe branded and generic drugs 
differently
 Simpler models forecast pharmaceutical life cycles with a greater level of 
accuracy than more complex ones.
 Most accurate of the current research 
 ARIMA for branded drugs
 Naïve + drift for generic drugs
 Aaker and Jacobson (1987) found that when modelling market share using 
the naive market share model, its predictive power was relatively high. 
 Brodie & de Kluyver (1987) found that a number of econometric market 
share models perform no better than a 'naive' model.' 
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Conclusions
 This research provides a basis for the NHS in employing any 
cost saving techniques when looking at how different 
pharmaceuticals are prescribed, and forecasting how they 
may be prescribed in the future
 As for pharmaceutical companies this research will allow 
them to discover, when it is best in the life cycle of the 
branded pharmaceutical to introduce strategies to prolong its 
life cycle and slow down the number of generic prescriptions 
written
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Thank you
Any Questions? 
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